» Articles » PMID: 25846246

MiR-154 Suppresses Non-small Cell Lung Cancer Growth in Vitro and in Vivo

Overview
Journal Oncol Rep
Specialty Oncology
Date 2015 Apr 8
PMID 25846246
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

miR-154 has been proven to act as a tumor suppressor in several types of tumors. However, its role in non-small cell lung cancer (NSCLC) remains unclear. Thus, the aim of this study was to investigate the effects of miR-154 on NSCLC tumorigenesis and development. Using real-time quantitative PCR (qRT-PCR), we analyzed expression of miR-154 at the transcriptional level in 40 NSCLC tumor tissues and matched adjacent normal tissues and the correlation with clinicopathological features of the patients. The miR-154 mimic was stably transfected into NSCLC A549 cells, and the effects of miR-154 on cancer cell proliferation, colony formation, cell cycle arrest, apoptosis, migration and invasion in vitro, and on the growth of in vivo xenografts were investigated. miR-154 expression levels were significantly downregulated in the NSCLC compared to the corresponding non-cancerous lung tissues (P<0.05), and decreased miR-154 expression was significantly associated with metastasis (P<0.001), larger tumor size (P<0.001) and advanced TNM stage (P<0.001). Furthermore, transfection of the miR-154 mimic into the NSCLC A549 cells was able to inhibit cell proliferation, colony formation, invasion and migration, and induce cell apoptosis and G0/G1 cell cycle arrest. Enforced expression of miR-154 also suppressed the growth of cancer cell xenografts in vivo. These findings indicate that miR-154 may become a potential target for miR-based therapy of NSCLC.

Citing Articles

Cell cycle associated miRNAs as target and therapeutics in lung cancer treatment.

Fariha A, Hami I, Tonmoy M, Akter S, Al Reza H, Bahadur N Heliyon. 2022; 8(10):e11081.

PMID: 36303933 PMC: 9593298. DOI: 10.1016/j.heliyon.2022.e11081.


The Role of the Selected miRNAs as Diagnostic, Predictive and Prognostic Markers in Non-Small-Cell Lung Cancer.

Szczyrek M, Bitkowska P, Jutrzenka M, Milanowski J J Pers Med. 2022; 12(8).

PMID: 36013176 PMC: 9410235. DOI: 10.3390/jpm12081227.


Influences HNSCC Development and Progression through Regulation of the Epithelial-to-Mesenchymal Transition Process and Could Be Used as a Potential Biomarker.

Tomaszewska W, Kozlowska-Maslon J, Baranowski D, Perkowska A, Szalkowska S, Kazimierczak U Biomedicines. 2021; 9(12).

PMID: 34944712 PMC: 8698850. DOI: 10.3390/biomedicines9121894.


Network potential identifies therapeutic miRNA cocktails in Ewing sarcoma.

Weaver D, Pishas K, Williamson D, Scarborough J, Lessnick S, Dhawan A PLoS Comput Biol. 2021; 17(10):e1008755.

PMID: 34662337 PMC: 8601628. DOI: 10.1371/journal.pcbi.1008755.


Potential Diagnostic and Prognostic Utility of miR-141, miR-181b1, and miR-23b in Breast Cancer.

Taha M, Mitwally N, Soliman A, Yousef E Int J Mol Sci. 2020; 21(22).

PMID: 33202602 PMC: 7697480. DOI: 10.3390/ijms21228589.